Emergent BioSolutions Inc. (EBS) SEC filings

EBSNYSEPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/3072% below fair value

$5.89−0.15 (-2.48%)

Close on Nov 12, 2026Market cap $302.00MP/E –Yield –

SEC filings

40 of Emergent BioSolutions's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Current report	8-K	Nov 4, 2026	Nov 4, 2026	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2026	Nov 3, 2026	SEC EDGAR
Current report	8-K	Nov 2, 2026	Nov 2, 2026	SEC EDGAR
Current report	8-K	Oct 16, 2026	Oct 16, 2026	SEC EDGAR
Current report	8-K	Sep 14, 2026	Sep 14, 2026	SEC EDGAR
Current report	8-K	Aug 18, 2026	Sep 1, 2026	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2026	Aug 6, 2026	SEC EDGAR
Current report	8-K	Aug 5, 2026	Aug 5, 2026	SEC EDGAR
Current report	8-K	Jun 26, 2026	Jun 29, 2026	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2026	May 1, 2026	SEC EDGAR
Current report	8-K	Apr 30, 2026	Apr 30, 2026	SEC EDGAR
Current report	8-K	Apr 29, 2026	Apr 30, 2026	SEC EDGAR
Current report	8-K	Apr 16, 2026	Apr 17, 2026	SEC EDGAR
Proxy statement	DEF 14A	Dec 31, 2025	Mar 20, 2026	SEC EDGAR
Current report	8-K	Feb 25, 2026	Mar 3, 2026	SEC EDGAR
Annual report	10-K	Dec 31, 2025	Feb 27, 2026	SEC EDGAR
Current report	8-K	Feb 26, 2026	Feb 26, 2026	SEC EDGAR
Current report	8-K	Jan 14, 2026	Jan 14, 2026	SEC EDGAR
Current report	8-K	Jan 12, 2026	Jan 12, 2026	SEC EDGAR
Current report	8-K	Dec 12, 2025	Dec 12, 2025	SEC EDGAR
Current report	8-K	Nov 7, 2025	Nov 12, 2025	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2025	Oct 30, 2025	SEC EDGAR
Current report	8-K	Oct 29, 2025	Oct 29, 2025	SEC EDGAR
Current report	8-K	Sep 5, 2025	Sep 11, 2025	SEC EDGAR
Current report	8-K	Sep 2, 2025	Sep 5, 2025	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2025	Aug 7, 2025	SEC EDGAR
Current report	8-K	Aug 6, 2025	Aug 6, 2025	SEC EDGAR
Current report	8-K	Jun 23, 2025	Jun 24, 2025	SEC EDGAR
Current report	8-K	May 23, 2025	May 23, 2025	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2025	May 8, 2025	SEC EDGAR
Current report	8-K	May 7, 2025	May 7, 2025	SEC EDGAR
Current report	8-K	Apr 30, 2025	May 6, 2025	SEC EDGAR
Current report	8-K	Mar 31, 2025	Mar 31, 2025	SEC EDGAR
Current report	8-K	Mar 19, 2025	Mar 24, 2025	SEC EDGAR
Proxy statement	DEF 14A	Dec 31, 2024	Mar 21, 2025	SEC EDGAR
Current report	8-K	Mar 10, 2025	Mar 10, 2025	SEC EDGAR
Annual report	10-K	Dec 31, 2024	Mar 4, 2025	SEC EDGAR
Current report	8-K	Mar 3, 2025	Mar 3, 2025	SEC EDGAR
Current report	8-K	Jan 15, 2025	Jan 15, 2025	SEC EDGAR
Current report	8-K	Jan 14, 2025	Jan 14, 2025	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in Emergent BioSolutions's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is EBS.

Compare: EBS vs AMPH · EBS vs AAPG · EBS vs PBH · EBS vs OPK · EBS vs MNKD

Revenue growth-17.7% · median 4.1%

Gross margin48.4% · median 54.5%

Operating margin-27.7% · median 7.9%

Net margin-40.2% · median -2.4%

Company	Revenue	Growth
PBH	$1.17B	+5.1%
AMPH	$745.79M	+3.1%
EBS	$649.10M	-17.7%
OPK	$501.64M	-8.3%
MNKD	$413.37M	+31.7%
AAPG	–	–

Company

Next earnings (est.): Feb 25, 2027, after close
Exchange: NYSE
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 900
Held by institutions: 87.1%
Auditor: Ernst & Young LLP
SEC CIK: 1367644

Advertisement
300 × 250

See a number that looks wrong?